Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's really damning AVXL with "faint praise" :)
The confusing part is, there seems to be no media/news recognition that Avxl was deleted from the Russell 3000. It is listed as deleted on a .PDF at the Russell website. Even the Benzinga Professional claims they know of no reasson why the stock dropped. Confusing to say the the least.
I would think more than 5%.LFIN dropped 48% over two trading sessions, March of ths year, after removal from the Russell.
Close today won't be the best price. Typically, a stock will drop for several days after being dropped by the Russell
Some stocks are hit hard, LFIN dropped 48% after being deleted from the Russell, a few months back.
.
It all depends LFIN dropped 48% over two days, after being removed from the Russell this March.
You may well be right. in that case the news from the Russell index is the announcement triggering the action
After hours being used for pre arranged trades. Jockeying for position. Usually seen prior to some type of announcement.
You are right. there is litlle, to nothing, other than irrational exuberence, to lead one to believe the company will be succesful. The biggest negative indicator, is the total lack of following by any respected biotech anyalyst. HC Wainwright, Maxium Group and SeethruEquity are the bottom of the barrell with no relationship to biotech.
Maxim Group has has handled financial transactions for AVXL in the past. Their opinion is biased.
There is no rally. The rise is do to the news on Institutional holdings. Even though nothing new there, it always creates a bit of a pop. Interesting that none of the large holders added at the bargain basement prices of the last 90 days. You are really "reaching" to suggest anu significant rise in the near future.
Sell on the news is not an unusual reaction. That having been said there doesn't appear to be much catalyst going on short term, I would look for the stock to slowly drop below $2 and remain there.
Yep, it is the cabal and their buddies the gremlins and unicorns. :)
This total nonsense has been going on for years. Absolutely no basis in fact.
It is going North because of the sudden rise in ECYT . A similar small drug research company, that languished below $2.00 for years before taking a recent rocket ride past $7.00. Several stock groups/clubs have set out to try to identify companies that may be in a similar situation as ECYT. AVXL has been mentioned and is apparently benefiting from the speculation.
Maxim has been a pumper for AVXL for a long time. Lowering the price target says volumes.
You will be lucky if $2.00 holds, the presentation showed little if any, change from the last 14 months of nothing.
This is year end selling accelerated, perhaps, by the company's "do nothing attitude" over the last 18 months. They are not acting like a company with a potential block buster product. That having been said, small biotech companies tend to do well in the first 90 days of each year as long as there isn't any specific bad news. AVXL will likely rise starting early next year.
Today's press release is nothing more than "fluff" reaching, at best, trying to "keep the ball in the air." The market reaction confirms that.
It falls in the "is that all you got" category. Anyone seriously interested in the company should see it as a negative.
I see Bill Gates is giving $50,000,000 to small biotech companies working on Alzheimer's Disease. I wonder what companies?
A small gambler who doesn't understand the recent info from Anavex on A273 and Alzheimer's. The info is of little significance and will lead to a steady drop on pps.
I know this may surprise you but most investors don't spend 24 hours a day on a stock thread obsessing about the stock. They make their purchase then check the news on it. Many have no idea on how to check the exact number of shares like you just did. Seeing that the CEO is regularly buying, gives them false sense of security in their investment
The bread crumbs buying is all part of the scam. Regular publicity that the CEO is buying, is most often not accompanied by number of shares purchased. Investors take the buying as a good sign without checking the number of shares actually purchased.Many don't know how to check.
375 shares? Talk about damned by faint praise. :)
The issuance of the patent was fully expected. We are seeing irrational exuberance here. The drop will start today and continue down during the week.
LPC is to desirable company financing, what payday loan companies are to desirable personal financing.
Finally, someone on this thread, sees it as it really is.
You are way over thinking it. The stock is news driven and no meaningful news equals a slow and steady drop. No news for an extended period of time, suggests problems, specifically with the Alzheimer study, which is the most popular with investors. Day dreaming about unlikely future gains, is not a strategy for dealing with this stock.
Keep on thinking it is all "manipulators." Perhaps it will make you feel better, when you loose your shirt down the road.
Your perceptions are likely accurate. This stock is probably not the gold mine many seem to think. Many are over invested in the stock, decisions based on hype and emotion.
Total compensation is the only way to compare.
Not even close to Missling
Charles S. Ramat
Consultant, Neurotrope, Inc.
Age Total Calculated Compensation This person is connected to 0 Board Members in 0 different organizations across 2 different industries.
Age 66, $559,317
As of Fiscal Year 2016
He is way over paid for a research/startup biotech. Go and compare.
Missling PhD. ExecutiveCompensation.
As President, Chief Executive Officer, Chief Financial Officer and Director at ANAVEX LIFE SCIENCES CORP, Christopher Missling PhD made $11,091,240 in total compensation.
I don't call that low. no matter how you want to spin it.
Thanks for mentioning the CEO, he draws a very large salary, in comparison to most start up Bio-techs. If the company succeeds or not, he will leave a multi millionaire. Another big red flag. It is not my intent to bash the company. It would be great, if everything worked out. This thread is almost exclusively positive pumpers. There needs to be some balance to it.
"I like the risk/reward under $10. " All though reward is not impossible, The risk/reward looks awfully low at this point. Don't invest the grocery money. :)
"when they can use LPC and go it alone" LPC financing, to a company, is a bit like you or I, taking our car to a title loan place, to obtain a 30% auto loan. Despite all that has been said, both ways, LPC financing is not a positive but a huge red flag. LPC and Maxim go hand in hand as bottom of the barrel entities.
Please tell me it's someone other than Lincoln. :)
That's your opinion, the only one that counts is the opinion held by folks willing to finance the drug, we are not seeing that interest.